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Abstract
Background: We present two melting curve analysis (MCA)-based semiquantitative real time
PCR techniques to detect the promoter methylation status of genes. The first, MCA-MSP, follows
the same principle as standard MSP but it is performed in a real time thermalcycler with results
being visualized in a melting curve. The second, MCA-Meth, uses a single pair of primers designed
with no CpGs in its sequence. These primers amplify both unmethylated and methylated sequences.
In clinical applications the MSP technique has revolutionized methylation detection by simplifying
the analysis to a PCR-based protocol. MCA-analysis based techniques may be able to further
improve and simplify methylation analyses by reducing starting DNA amounts, by introducing an
all-in-one tube reaction and by eliminating a final gel stage for visualization of the result. The current
study aimed at investigating the feasibility of both MCA-MSP and MCA-Meth in the analysis of
promoter methylation, and at defining potential advantages and shortcomings in comparison to
currently implemented techniques, i.e. bisulfite sequencing and standard MSP.
Methods: The promoters of the RASSF1A (3p21.3), BLU (3p21.3) and MGMT (10q26) genes were
analyzed by MCA-MSP and MCA-Meth in 13 astrocytoma samples, 6 high grade glioma cell lines
and 4 neuroblastoma cell lines. The data were compared with standard MSP and validated by
bisulfite sequencing.
Results: Both, MCA-MSP and MCA-Meth, successfully determined promoter methylation. MCA-
MSP provided information similar to standard MSP analyses. However the analysis was possible in
a single tube and avoided the gel stage. MCA-Meth proved to be useful in samples with intermediate
methylation status, reflected by a melting curve position shift in dependence on methylation extent.
Conclusion: We propose MCA-MSP and MCA-Meth as alternative or supplementary techniques
to MSP or bisulfite sequencing.
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DNA methylation in promoter regions has a regulatory
effect on gene transcription. The conversion by covalent
binding of a methyl residue from cytosine to 5-methylcy-
tosine (m5C) at CpG dinucleotides occurs in both,
prokaryotic and eukaryotic genomes and represents the
most abundant methylated base in the genome of verte-
brates. Areas of high CpG dinucleotide density, so called
"CpG islands", are spread throughout the genome and
usually map to gene promoter regions. Almost half of the
genes in our genome have such CpG-rich promoter
regions [1]. Methylation of CpG islands is associated with
histone deacetylation and transcriptional silencing [2]
and it is essential for normal embryonic development,
genomic imprinting and X-chromosome inactivation. It
also plays a role in cancer, as tumor suppressor gene pro-
moter methylation leads to their inactivation.
In standard PCR and cloning procedures, information
about m5C and other covalent base modifications in
genomic DNA is lost. Therefore, PCR methods for detect-
ing and mapping m5C in specific genes rely on treatment
of genomic DNA with methylation-sensitive restriction
endonucleases or sodium bisulfite treatment before
amplification. A specific target sequence can subsequently
be amplified with primers specific for bisulfite-converted
DNA and examined for its m5C content. The gold stand-
ard among bisulfite methods is genomic sequencing, that
provides a positive display of m5C at specific CpG sites in
virtually any stretch of DNA [3]. More simple methods
using bisulfite-converted DNA as template include meth-
ylation-specific PCR (MSP) [4], methylation-sensitive sin-
gle nucleotide primer extension [5] and procedures based
on the use of restriction endonucleases [6,7]. MSP is
designed to specifically amplify either methylated or
unmethylated DNA by using primers that differentiate the
bisulfite-converted methylated sequence from the
unmethylated sequence [4]. Another method for analyz-
ing promoter methylation status is the combined bisulfite
restriction analysis (COBRA) [7]. The degree of methyla-
tion is determined by restriction enzyme digestion on CG-
containing restriction sites, whereas methylated cytosine
residues are protected from bisulfite conversion and sub-
sequent digestion. The above methods entail a two step
procedure, an initial PCR amplification and subsequent
product analysis, usually by gel electrophoresis. Further-
more, with the exception of genomic sequencing, these
are limited to the analysis of one or a few CpG sites in
each setting.
A specific real-time quantitative MSP method based on
detection of a fluorescent signal produced proportionally
during polymerase chain reaction (PCR) amplification
was developed in the 1990s and allows the rapid and
highly accurate analysis of methylation levels in tissue
samples [8,9]. More recently, a quantitative real-time
methylation assay, which utilized the fluorescence-based
TaqMan technology was developed [10]. This technique,
called MethyLight, provides a sensitive and quantitative
assay of methylated DNA. However, TaqMan technology
requires the design of a fluorogenic probe, possibly a new
set of primers and is relatively expensive.
Of note, high-throughput methodologies have been
developed allowing quantitative methylation analyses tar-
geting individual CpG dinucleotide residues, i.e. pyro-
sequencing and matrix-assisted laser desorption/ioniza-
tion time-of-flight mass spectrometry (MALDI TOF MS)
[11,12]. However, both demand expensive hardware,
which may not be easily accessible for many institutions,
and either need time-consuming and sensitive samples
preparation (MALDI-TOF) or are still limited to a rather
short target sequence not suitable for screen purposes
(pyrosequencing).
We describe 2 in-tube PCR assays for the detection of aber-
rant DNA methylation that use a thermal cycler integrated
with a fluorometer and exploit differences in melting tem-
perature (Tm) between methylated and unmethylated
DNA after bisulfite treatment. Both real-time PCR tech-
niques use the SYBR Green dye, which binds to double-
stranded DNA. Bisulfite modified DNA is amplified and a
melting curve of the PCR product is performed. After
bisulfite conversion, the methylated sequence conserves
the CG-dinucleotide residues, while these convert to TG
dinucleotides in the unmethylated sequence, thereby
reducing the melting temperature of the DNA fragment.
Sequences with a high CG- to TG-conversion reflect
unmethylated DNA. During melting curve analysis these
will therefore reveal melting temperatures with peaks
lower than those of CG-rich, methylated DNA sequences.
The first assay we describe is the Melting Curve Analysis-
Methylation Specific PCR (MCA-MSP), that uses MSP
primers for the amplification of bisulfite modified DNA.
Like standard MSP it implements two sets of primers, one
set specific for unmethylated and another set specific for
methylated DNA. The reactions are carried out in two sep-
arate tubes.
Our second assay, the Melting Curve Analysis-Methyla-
tion assay (MCA-Meth), uses a single set of primers that
amplifies both the methylated and the unmethylated
DNA, as the primer-target annealing sequences, just like
those of bisulfite sequencing primers, do not contain any
CpG dinucleotides. The methylation status of the sample
will be assigned according to the pattern of peaks in the
melting curve.Page 2 of 14
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for our study: RASSF1A (3p21.3, a Ras oncogene associ-
ated protein that promotes cell cycle arrest in promet-
aphase), BLU (3p21.3, a DNA binding protein that
regulates the entry of the cell into the cell cycle) and
MGMT (10q26.1, a DNA repair gene that eliminates alkyl
groups from the O6 position of guanine). Many studies
have been performed on the promoters of these genes
demonstrating that the methylation status is relevant for
tumor biology [13-19]. We have studied the methylation
status and gene expression of these three tumor suppres-
sor genes in 4 neuroblastoma cell lines, 6 astrocytoma cell
lines and 13 primary astrocytic tumor samples.
Methods
Samples and cell lines
Thirteen primary astrocytic tumors and 10 cell lines (6
astrocytoma cell lines: A172, GOS-3, MOG-G-CCM,
T98G, U87MG, U118; and 4 neuroblastoma cell lines:
MC-IXC, SIMA, IMR32, SK-N-MC) were used for the
study. Human samples were frozen at -80°C immediately
after surgery. Cell lines were provided by the American
Type Culture Collection (MC-IXC), the European Collec-
tion of Cell Culture (A172, MOG-G-CCM, T98G, and
U87MG), the Deutsche Sammlung von Mikroorganismen
und Zellkulturen (IMR-32, SIMA, SK-N-MC, GOS-3) and
the American Type Cell Collection (U118).
MC-IXC, IMR32, SIMA and SK-N-MC cell lines were
grown with Dubelcco's modified Eagle's medium
(DMEM+ L-Glutamax), supplemented with 10% fetal
bovine serum (FBS), 1% penicillin/streptomycin and
0.1% anfotericine B, at 37°C with 5% CO2. GOS-3, T98G,
MOG-G-CCM, A172, U87MG and U118 cell lines were
cultured with RPMI+L-Glutamax medium, supplemented
with 10% fetal bovine serum (FBS), 1% penicillin/strepto-
mycin and 0.1% anfotericine B, at 37°C with 5% CO2.
DNA extraction and bisulfite treatment
DNA from the cell lines was purified by the Wizard®
Genomic DNA Purification Kit (Promega) according to
manufacturer's instruction. 1 μg genomic DNA was
bisulfite modified by the CpGenome™ DNA Modification
Kit (Chemicon® International), following manufacturer's
protocol. Modified DNA was purified, then eluted in 1
mM TE pH 8, and used immediately or stored at -80°C for
up to six months. Blood genomic DNA and in vitro meth-
ylated DNA (Genome™ Universal Methylated DNA,
Chemicon® International), were used as negative and pos-
itive controls, respectively, for the methylation status of
DNA.
MSP
The methylation specific PCRs were carried out with 60 ng
of bisulfite modified DNA in a total volume of 25 μl,
which contained 2.5 μl 10× reaction buffer, 2–2.5 mM
MgCl2, 0.2 mM of each dNTP, 10 pmol forward and
reverse primers, 5% DMSO and one unit of AmpliTaq
Gold™ polymerase (Roche), in a T3 thermocycler of Biom-
etra®.
Oligonucleotides for RASSF1A and MGMT (Table 1) were
designed using the MethPrimer software [20]. Primers for
BLU (Table 1) were described previously [13]. PCR reac-
tions were denatured at 94°C for 10 min, followed by
36–38 cycles of 45 s at 94°C, 30–45 s at the correspond-
ing annealing temperature for each gene (Table 1), 30–45
s at 72°C, followed by a final extension step at 72°C for
10 min. PCR products were visualized in a 2% agarose gel
stained with ethidium bromide at a final concentration of
0.1 μg/ml.
MCA-MSP
MCA-MSP (Melting Curve Analysis-Methylation Specific
PCR) was carried out with 3–6 ng of bisulfite modified
DNA in a total volume of 25 μl, containing 12.5 μl of 2 ×
IQ™ SYBR Green Supermix (Bio-Rad) and 2.5 pmol of
primers (either the primers for the methylated or the
unmethylated sequence). The primers for RASSF1A,
MGMT and BLU genes are the ones described for MSP (see
Table 1).
The reactions were heated at 94°C for 10 min, followed
by 45 cycles of 30 s at 94°C, 30 s at the corresponding
annealing temperatures (Table 1), 30 s at 72°C, and 30 s
at 76–77°C. We modified the MSP protocol by addition
of an extra incubation step at 76–77°C in each cycle, to
overcome the primer dimer artifact, as described previ-
ously [21]. After gene amplification, the melting curve
analysis was performed as follows: from 70°C to 90°C,
the temperature was increased by 0.5°C every 30 s. Both
amplification and melting curve were carried out in an
IQ5 Multicolor Real-Time PCR Detection System (Bio-
Rad).
MCA-Meth
MCA-Meth (Melting Curve Analysis-Methylation assay)
was carried out with 3–6 ng of bisulfite modified DNA in
a total volume of 25 μl, containing 12.5 μl of 2× IQ™ SYBR
Green Supermix (Bio-Rad) and 2.5 pmol of primers.
The primers for RASSF1A, MGMT and BLU genes (Table
1) were designed using the MethPrimer software [20].
These primers do not contain any CpG in their sequence.
Therefore they will amplify the target DNA regardless of
its methylation status. The reactions were heated at 94°C
for 10 min, followed by 40–45 cycles of 30 s at 94°C, 30
s at the corresponding annealing temperature (Table 1),
and 30 s at 72°C. For the MGMT gene, an extra step of 30
s at 76°C was added in each cycle, to avoid the signal ofPage 3 of 14
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ing the same protocol as for the MCA-MSP assay. Both
amplification and melting curve were carried out in an
IQ5 Multicolor Real-Time PCR Detection System (Bio-
Rad).
Bisulfite sequencing
Initially, 12 ng of bisulfite treated DNA of a target pro-
moter region were amplified in a PCR reaction with a total
volume of 20 μl, containing 10 μl of 2× PCR Mastermix-Y
(PEQLAB) and 5 pmol of bisulfite sequencing primers.
The oligonucleotides were designed using the MethPrimer
software. The reactions were denatured at 95°C in a first
PCR step for 5 min, then 38 cycles of 30 s at 95°C, 1 min
at the corresponding annealing temperature for each gene
(Table 1), and 2 min at 72°C, followed by a final exten-
sion step at 72°C for 10 min, in a T Gradient thermocycler
(Biometra).
Secondly, the PCR product was plasmid incorporated
using the One Shot E. coli cells and the TOPO TA Cloning
Kit PCR®2.1-TOPO Vector (Invitrogen). Cells were then
plated and grown overnight on LB plates containing X-Gal
and 50 mg/ml ampicillin and 50 mg/ml kanamycin. In
order to validate the colonies with the right insert, colony
PCR was then performed on 8 white colonies, with 10
pmol of M13 primers and 10 μl of 2× PCR Mastermix-Y
(PEQLAB) in a total volume of 20 μl. The reactions were
heated at 94°C in a first PCR step for 5 min; 33 cycles of
30 s at 94°C, 1 min at 55°C, and 10 s at 72°C; followed
by an extension step of 10 min at 72°C.
PCR products harboring the insert were digested with
EXOSAP-IT® exonuclease (USB Corp.) and the sequencing
PCR was performed with 1 μl Big Dye® Terminator v1.1
cycle sequencing PR-100, 1.5 μl Big Dye® Terminator v1.1,
v3.1 5× sequencing buffer (Applied Biosystems), 5 pmol
of M13 reverse primer and 1 μl of digested DNA in a total
volume of 10 μl. The reaction mixture was denatured at
93°C for 5 min, followed by 25 cycles of 10 s at 96°C, 15
s at 57°C and 4 min at 60°C. This sequencing PCR prod-
uct was cleaned in Sephadex® G-50 (Sigma-Aldrich) col-
umns and then sequenced in an ABI PRISM 377 DNA
Table 1: List of oligonucleotides used for MSP, MCA-Meth and bisulfite sequencing of RASSF1A, MGMT and BLU genes.
MSP and MCA-MSP MCA-Meth bisulfite sequencing
RASSF1A UF: 5'-GAGAGTGTGTTTAGTTTTGTTTTT-
3'
F: 5'-
AGTTTTTGTATTTAGGTTTTTATTG-3'
F: 5'-
ATAGTAAAGTTGGTTTTTAGAAATA-
3'
UR: 5'-
CCCATACTTCACTAACTTTAAACAC-3'
R: 5'-
AACTCAATAAACTCAAACTCCCC-3'
R: 5'-
CAACTCAATAAACTCAAACTCCCCC
-3'
MF: 5'-GAGAGCGCTTTAGTTTCGTTTTC-
3'
MR: 5'-
ACCCGTACGTTCGCTAACTTTAAACG-3'
MGMT UF: 5'-
GAGAGATTTGTGTTTTGGGTTTAGTG-3'
F: 5'-GGTTTGGGGGTTTTTGATTAG-3' F1: 5'-
GGTATTAGGAGGGGAGAGATT-3'
UR: 5'-
CCTTCAACCAATACAAACCAAACAA-3'
R: 5'-
CCTTTTCCTATCACAAAAATAATCC-
3'
R1: 5'-
TATACCTTAATTTACCAAATAACCC-
3'
MF: 5'-ATTCGCGTTTCGGGTTTAGC-3' F2: 5'-
GTAAATTAAGGTATAGAGTTTTAGG-
3'
MR: 5'-CGACCGATACAAACCGAACG-3' R2: 5'-AACTATCCCAACATATCC-3'
BLU UF: 5'-
TTTGTGGGTTATAGTTTGAGAAAGTG-3'
F: 5'-
AAGGATTTGGAGTTTAGGAGAGATT-
3'
F: 5'-
AAGGATTTGGAGTTTAGGAGAGATT
-3'
UR: 5'-AACAAATTAACCACACCTACAC-3' R: 5'-
CCAAAATCTAAAACAAAACAATTAC-
3'
R: 5'-
CCAAAATCTAAAACAAAACAATTAC
-3'
MF: 5'-
TTCGTGGGTTATAGTTCGAGAAAGCG-3'
MR: 5'-AACGAATTAACCGCGCCTACGC-3'
Annealing temperatures for every set of primers:
MSP: RASSF1A UF and UR: 62°C; RASSF1A MF and MR:58°C; MGMT UF and UR: 62°C; MGMT MF and UR: 62°C; BLU UF and UR: 60°C; and BLU 
MF and MR: 66°C.
MCA-Meth: RASSF1A F and R: 58°C; BLU F and R: 56°C; and MGMT F and R: 61°C.
Bisulfite sequencing: RASSF1A F and R: 61°C; MGMT F1 and R1: 58°C; MGMT F2 and R2: 58°C; and BLU F and R: 56°C.Page 4 of 14
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lysed using the Sequencher Software version 4.2.
Results
Optimizing the real-time PCR
Diluting the template DNA
In order to optimize the conditions for the real time PCRs,
we tried to minimize as much as possible the amount of
DNA used in the PCR reactions. For standard MSP we usu-
ally take 60 ng of bisulfite converted DNA. We tried 1:5
(12 ng), 1:10 (6 ng), 1:20 (3 ng), 1:30 (2 ng), 1:40 (1.5
ng) and 1:50 (1.2 ng) dilutions of the bisulfite modified
DNA for our real-time PCR experiments. As the amount of
DNA was decreased, the amplification started later, giving
higher CT (threshold cycle) values: CT = 34.7 for 1:5 dilu-
tion, CT = 37.6 for 1:10 dilution, CT = 38.7 for 1:20 dilu-
tion, CT = 39.7 for 1:30 dilution and CT = 40.5 for 1:40
dilution. We did not obtain any results with the 1:50 dilu-
tion. We also observed that as the amount of DNA
decreased, the reproducibility of the reaction was lower,
giving a higher inter-tube and inter-assay variation,
mainly in the 1:30 (2 ng) and 1:40 (1.5 ng) dilutions
(data not shown). Thus, we recommend using the 1:10 (6
ng) or 1:20 (3 ng) dilution to obtain a good balance
between DNA economy and an assay of good quality.
Overcoming primer dimers
The SYBR-Green dye binds to double stranded DNA. This
holds true for the specific product but also for primer dim-
ers, if they are formed during the PCR reaction. To over-
come this problem we included an extra incubation step
of 76–77°C for 30 s after the 72°C extension step [21] in
the PCRs in which primer dimers gave a strong signal. The
extra incubation step dissociates the double-stranded
primer dimers into single-stranded DNA while leaving the
PCR products intact. Thus the fluorescence signal
obtained at this higher temperature is only due to the spe-
cific PCR products. The temperature of this extra step has
to be higher than the melting temperature of the primer
dimers and lower than the melting temperature of the spe-
cific products, and can vary between different PCRs.
The extra step was added in the two PCRs performed for
every gene studied by MCA-MSP, as primer dimers were
generated in all these cases. In contrast, it was only neces-
sary for MGMT amplification by MCA-Meth (Table 2).
Comparison of the MSP, MCA-MSP and MCA-Meth 
techniques
Promoter hypermethylation of RASSF1A, BLU and MGMT
was assessed by MCA-MSP and MCA-Meth (Figure 1), and
compared to conventional MSP. The three techniques
were significant for RASSF1A promoter hypermethylation
in all tumor samples and all glioma cell lines.
MSP revealed BLU promoter hypermethylation in cell
lines GOS-3, A172, MOG-G-CCM, SIMA and IMR-32.
U87MG, T98G, U118, SK-N-MC and MC-IXC were
unmethylated. Similar results were obtained by MCA-
MSP or MCA-Meth in all cell lines except for IMR32,
which appeared unmethylated in the MCA-MSP and
MCA-Meth analyses (Figure 2).
We received matching results in all three techniques for 10
out of 13 tumor samples for the BLU gene promoter. Two
tumors were methylated and eight were unmethylated. All
three remaining tumors appeared methylated by MSP,
while two were unmethylated amd one was methylated by
MCA-MSP and MCA-Meth (Tables 3 and 4).
GOS-3, A172, MOG-G-CCM, T98G, U87MG, U118 and
IMR-32 cell lines showed MGMT promoter hypermethyl-
ation by all three techniques, while SIMA and MC-IXC
harbored an unmethylated promoter. Cell lines SK-N-MC
and MC-IXC produced ambiguous results. For SK-N-MC
MGMT promoter hypermethylation was detected by both
MCA-MSP and MCA-Meth, whereas conventional MSP
was significant for an unmethylated MGMT promoter. For
MC-IXC MCA-Meth analysis showed evidence of pro-
moter hypermethylation but MSP and MCA-MSP were in
favor of an unmethylated promoter. In 8 of 13 tumor
samples all three techniques produced homogeneous
results (4 unmethylated and 4 methylated MGMT pro-
moters). Conflicting results were seen in the other 5
tumors. One of these samples showed hypermethylation
by MSP but neither by MCA-MSP nor MCA-Meth. The
remaining 4 samples were positive for a hypermethylated
promoter by MSP and MCA-Meth, but revealed no evi-
dence for promoter methylation by MCA-MSP (Tables 3
and 4, Figure 3).
Validation of the power of the presented techniques of 
promoter hypermethylation with bisulfite sequencing
In most of the samples analyzed, the results obtained with
the 3 techniques matched. However, ambigiuous results
were obtained for some samples. This might be due to a
Table 2: CT values obtained after MGMT amplification of no 
methylated DNA (from blood), in vitro methylated DNA (IMD) 
and no template control (H2O) by MCA-Meth analysis, with and 
without the adition of the extra incubation step. CT values get 
reduced (primer dimers do not get amplified) when using the 
incubation step. No amplification at all is produced in the no 
template control (H2O), meaning that the CT value of 36.8 
corresponded to primer dimer amplification.
Blood IMD H2O
CT without step 35.5 38.6 36.8
CT with step 34.2 38.3 -Page 5 of 14
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hypermethylation or to the fact that the primers used in
the different assays do not exactly target the same CpGs in
the promoter region. To clarify this question, we per-
formed bisulfite sequencing of the area of the promoter
covered by the two types of primers used for the different
techniques in each gene.
Also, we observed that in the MCA-MSP or MCA-Meth
techniques some samples gave a peak in the melting curve
at an intermediate temperature between the peaks corre-
sponding to the fully methylated or unmethylated DNA.
These peaks suggest an intermediate amount of methyl-
ated cytosines in the samples. Bisulfite sequencing was
performed to verify our hypothesis.
Two cell lines were sequenced in the promoter of the BLU
gene: U118 and A172. Bisulfite sequencing revealed that
U118 was unmethylated and A172 was methylated. These
results were consistent with the results obtained with MSP
and MCA-Meth techniques (Table 3).
Two astrocytomas (samples 7 and 30) and the cell line
T98G were sequenced in the promoter of the RASSF1A
gene: sample 30 and the T98G cell line were strongly
methylated while sample 7 presented a lower degree of
methylation (3 to 16 of the 32 CpGs analyzed were meth-
ylated in the different clones). Sample 30 and the T98G
cell line appeared methylated by all the other techniques
as well. However, sample 7 was methylated by MSP and
MCA-Meth, the latter in a very low proportion (Tables 3
and 4).
Two other astrocytomas (samples 26 and 28) and the
U87MG cell line were sequenced in the promoter of the
MGMT gene (Figure 3): sample 26 was unmethylated and
sample 28 was strongly methylated. These results are con-
sistent with the results obtained with the other 3 tech-
niques (Table 4). U87MG cell line was "half" methylated
by bisulfite sequencing, corresponding with a peak in an
intermediate position in the MCA-Meth. MSP results
show that this cell line is methylated (Table 3). Thus, the
MCA-Meth and MCA-MSP techniques can detect the half-
methylated status of the promoter and differentiate it
from a fully methylated promoter, whereas MSP can not.
MCA-Meth analysis in RASSF1A gene for the astrocytoma sample 33Figure 1
MCA-Meth analysis in RASSF1A gene for the astrocytoma sample 33. The graph shows the unmethylated control peak 
(blood DNA) in red, the methylated control peak in green, the no template control in blue, and the sample with both the 
unmethylated and the methylated peaks, in brown. This result suggests a mixture of methylated and unmethylated DNA in this 
sample. It might be due to the contamination of the tumor sample with normal adjacent tissue.Page 6 of 14
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Meth
We mixed unmethylated and methylated DNA at different
percentages (0%, 5%, 10%, 20%, 30%, 40%, 50%, 60%,
70%, 80%, 90%, and 100%). Then we performed the
MCA-Meth analysis for the three genes (RASSF1A, BLU
and MGMT) in triplicate and measured the height of the
peaks obtained and calculated the average height for each
triplicate. As expected, the 0% gave the unmethylated
peak only and 100% only the methylated peak, while the
intermediate percentages gave the two peaks, increasing
the height of the unmethylated peak proportionally to the
amount of unmethylated DNA and increasing the height
of the methylated peak proportionally to the amount of
methylated DNA (Figure 4). Then, we measured the trip-
licates of the peaks of the tumor samples and cell lines and
interpolated those values into the graphs obtained with
the percentages above (Figure 4), to obtain a semiquanti-
tative idea of the amount of methylated-unmethylated
DNA (Table 3, Table 4).
Discussion
Several methodologies have been developed to assess pro-
moter methylation. We present here two techniques that
exploit the differences in melting temperature (Tm)
between methylated and unmethylated alleles after
bisulfite treatment and allow for the distinction of alleles
harboring different percentages of methylated CpG dinu-
cleotides. After bisulfite treatment, a methylated sequence
conserves the CG pairs while an unmethylated sequence
presents changes to TG pairs. This change in CG content
results in a variation of the melting temperature of a par-
MCA-MSP analysis in BLU and MGMT genes for the A172 and SIMA cell linesFigure 2
MCA-MSP analysis in BLU and MGMT genes for the A172 and SIMA cell lines: The graphs show the unmethylated 
control peak (blood DNA) in red, the methylated control peak in green, the no template control in blue and the cell line peak, 
in brown. a) PCR for the unmethylated sequence, BLU gene, A172 cell line: only the blood DNA gives a peak, thus the cell line 
contains no unmethylated DNA. b) PCR for the methylated sequence, BLU gene, A172 cell line: the methylated DNA and the 
cell line give peak, thus the A172 cell line is methylated for the BLU gene. c) PCR for the unmethylated sequence, MGMT gene, 
SIMA cell line: the blood DNA and cell lines give peak, thus the cell line is unmethylated. d) PCR for the methylated sequence, 
MGMT gene, SIMA cell line: only the methylated DNA gives a peak, thus the cell line is not methylated.Page 7 of 14
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and melting curve shapes, it was possible to assign a meth-
ylation status to the tested samples.
Melting curves of methylated and unmethylated DNAs are
tested in two separate reactions when using Melting Curve
Analysis-Methylation Specific PCR (MCA-MSP), as in
standard MSP. Thus, we simply look for the presence or
absence of product amplification that will give a single
melting curve peak (Figure 2). Therefore, MCA-MSP does
not require a difference in the Tm between the methylated
and unmethylated DNA. In theory, it may be possible to
multiplex MCA-MSP assays by performing a single PCR
reaction that includes both methylated and unmethylated
specific primers. However, multiplexing assays would
require a difference in the Tm between methylated and
unmethylated peaks, and both methylated and unmethyl-
ated specific primers to anneal at the same temperature
during the PCR.
The Melting Curve Analysis-Methylation assay (MCA-
Meth) only uses one set of primers that do not include
methylation susceptible CpGs on its sequence. This set of
primers, similar to bisulfite sequencing primers, amplifies
both the methylated and the unmethylated sequence. The
difference will become evident in the melting curves, as
Table 3: BLU, RASSF1A and MGMT genes hypermethylation in astrocytoma and neuroblastoma cell lines.
BLU RASSF1A MGMT
MSP MCA-MSP MCA-Meth Seq MSP MCA-MSP MCA-Meth Seq MSP MCA-MSP MCA-Meth Seq
U87 U U 0% U+M U+M 36% M UM UM
GOS 3 M M M 100% M M M 100% U+M U+M U+M 78%
A 172 M M M 100% M M U+M M 100% M M UM
MOG U+M M U+M 53% M UM UM U+M UM UM
T98G U U U 0% M M M 67% M M UM M 61%
U118 U U 0% U M M 100% M M 98%
SIMA U+M M M 76% M M M 100% U U U 0%
IMR 32 U+M U U 0% M M M 98% U+M UM M 86%
SK-N-MC U U U 0% M M M 100% U+M U UM
MC-IXC U U U 0% M M M 100% U U U 0%
U, unmethylated peak or band; M, methylated peak or band; U+M, sample producing both methylated and unmethylated peaks or bands; MU, 
sample producing only one peak at an intermediate temperature; blank spaces: not determined analyses. The percentage of fully methylated DNA 
molecules present in the samples (semiquantitative methylation study) is shown for the MCA-Meth in the M and U+M cases. On the contrary, no 
percentage appears in the the UM cases, as the UM corresponds to partially methylated DNA molecules, that can not be semiquantitatively studied 
according to the curve obtained with different proportions of fully methylated DNA.
Table 4: BLU, RASSF1A and MGMT genes hypermethylation in astrocytoma tumor samples.
BLU RASSF1A MGMT
Sample MSP MCA-MSP MCA-Meth MSP MCA-MSP MCA-Meth Seq MSP MCA-MSP MCA-Meth Seq
7 A III U U 0% U+M U+M <5% U U+M U+M <5%
8 A III-IV U U U 0% U+M U+M U+M <5% U+M U U+M <5%
12 GBM U U U 0% U+M M U+M <5% U U U 14%
13 GBM U+M U+M U 22% U+M M U+M 20% U U U 0%
26 GBM U+M U U 0% U+M M U+M <5% U U U 0% U
28 GBM U+M U U+M <5% U+M M U+M 12% M U+M M 100% M
30 GBM U+M U+M U+M 65% U+M U+M U+M 72% M U+M U+M UM
33 A III U+M U+M U+M 57% U+M U+M U+M 46% U+M U+M UM UM
45 GBM U U U 0% U+M U+M U+M <5% U+M U U 0%
46 GBM U U U 0% U+M U+M U+M <5% U+M U U+M <5%
47 A III-IV U U U 0% U+M U+M U+M 22% U+M U U+M <5%
49 GBM U U U 0% U+M U+M U+M <5% U U U 0%
51 GBM U U U 16% U+M U+M U+M <5% U+M U UM
U, unmethylated peak or band; M, methylated peak or band; U+M, sample producing both methylated and unmethylated peaks or bands; MU, 
sample producing only one peak at an intermediate temperature; blank spaces: not determined analyses. The percentage of fully methylated DNA 
molecules present in the samples (semiquantitative methylation study) is shown for the MCA-Meth in the M and U+M cases. On the contrary, no 
percentage appears in the the UM cases, as the UM corresponds to partially methylated DNA molecules, that can not be semiquantitatively studied 
according to the curve obtained with different proportions of fully methylated DNA.Page 8 of 14
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BMC Cancer 2008, 8:61 http://www.biomedcentral.com/1471-2407/8/61the methylated product will have a higher melting tem-
perature than the unmethylated product (Figure 1, Figure
3). However, it can be difficult to find a good set of prim-
ers with these characteristics for some genes.
The two techniques described here, both using the SYBR
Green dye and Melting Curve Analysis, provide several
advantages over standard MSP and other commonly used
methylation screening methods. Experimental protocols
are simple, can be carried out in high throughput formats
(96 or 384-well microplates) allowing very little sample
manipulation and do not need a gel phase for result doc-
umentation. Classical MSP necessitates 10–20 ng DNA,
while successful MSP-Meth amplification is possible with
as little as 6 ng DNA. This may be especially important
when analyzing DNA derived from archival material. An
additional advantage of the MCA-Meth over MCA-MSP is
that the analysis can be done in a single all-in-one-tube-
reaction, instead of two reactions usually required for
MCA-MSP and MSP. Thereby, it is easier to handle, less
prone to contamination by other samples, saves DNA for
additional analyses on those samples and shortens analy-
sis time.
Hypermethylation analysis by bisulfite sequencing, MSP and MCA-Meth of MGMT gene in astrocytoma samples 26, 28 and in the U87MG cell lineFigu e 3
Hypermethylation analysis by bisulfite sequencing, MSP and MCA-Meth of MGMT gene in astrocytoma sam-
ples 26, 28 and in the U87MG cell line. a) Bisulfite sequencing results of the MGMT gene in astrocytoma samples 26 and 28 
and in the U87MG cell line. Black squares indicate methylated CpG dinucleotides and white squares indicate unmethylated CpG 
dinucleotides in promoter sequences. Above the diagrams, the area of the promoter analyzed by MSP, MCA-Meth and bisulfite 
sequencing is indicated. The 5'- and 3'-priming sites of M- and U-primers are indicated as small black dots representing the CpG 
sites incorporated in the primer sequence. The position of CpGs in relation to the CpG-island as well as the number of CpGs 
analyzed are indicated in the brackets behind the respective techniques. On the right, the diagrams of peaks obtained with the 
sequencing software: it can be observed how after the bisulfite treatment, the cytosines remain unchanged in the methylated 
sample, while there is a shift to thymine in the unmethylated sample. b) MSP results of MGMT in astrocytoma samples 26, 28 
and in the U87MG cell line. U: PCR with primers specific for the unmethylated sequence; M: PCR with primers specific for the 
methylated sequence. c) MCA-Meth results of MGMT in astrocytoma samples 26, 28 and in the U87MG cell line. The graphs 
show the unmethylated control peak (blood DNA) in red, the methylated control peak in green, the no template control in 
blue and the sample or cell line peak, in brown. It can be observed how in the case of the U87MG cell line, the amount of meth-
ylated cytosines in the area of the promoter analyzed by bisulfite sequencing is intermediate between the sample 26 (unmethyl-
ated) and sample 28 (fully methylated). Of note, MCA-Meth appreciates this inhomogeneous sequence methylation pattern of 
U87MG with a melting curve peak in an intermediate position as compared to the unmethylated (26) and the methylated sam-
ple (28).Page 9 of 14
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BMC Cancer 2008, 8:61 http://www.biomedcentral.com/1471-2407/8/61An advantage of these real time based techniques is the
possibility of quantifying the presence of methylated and
unmethylated DNA. If primer dimer signals were avoided,
and if there were no unspecific product amplification, the
quantity of fluorescence detected should be proportional
to the quantity of specific amplification product, giving
the possibility of quantification. In MCA-MSP, quantifica-
tion can be done by analyzing the amplification curve tak-
Determination of the percentage of fully methylated MGMT by MCA-MethFigu e 4
Determination of the percentage of fully methylated MGMT by MCA-Meth. a) The graph shows the melting peaks 
for the different percentages of methylated and unmethylated DNA. The increase and the decrease in the height of the specific 
peaks in the different percentages can be observed. Red: 0% methylated DNA. Green: 100% methylated DNA. Purple: 5%, 10%, 
20%, 30%, 40%, 50%, 60%, 70%, 80% and 90% methylated DNA. b) Graph representing the linear relationship between the % of 
methylated DNA and the height of the methylated peak in the melting curve of the MGMT gene. As the % of methylated DNA 
increases (0%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% and 100%) the peak appears higher. Measuring the height of 
the peak of each sample, and interpolating the data in the graph, we can obtain an approximate % of fully methylated DNA 
present in each sample.Page 10 of 14
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BMC Cancer 2008, 8:61 http://www.biomedcentral.com/1471-2407/8/61ing into account the CT (threshold cycle). Other authors
performed and compared MCA-MSP and real-time quan-
titative PCR methylation using TaqMan probes. With the
MCA-MSP protocol, the CT values at most concentrations
were comparable to TaqMan, but the sensitivity was lower
[21]. We hypothesized that the height of the peaks was
proportional to the amount of product in MCA-Meth. To
confirm this hypothesis, we performed a series of dilu-
tions of fully methylated DNA and run MCA-Meth PCRs
for three genes (RASSF1A, BLU and MGMT) in triplicate,
measured the height of the peaks obtained and calculated
the average height for each triplicate. We obtained a linear
relationship between the percentage of fully methylated
DNA and the height of the peak (Figure 4). We succeeded
in detecting as little as 5% of methylated DNA, with 6 ng
of starting DNA in the PCR. The sensitivity of the assay
might be higher if the amount of template DNA in the
reaction was increased.
Besides distinguishing methylated from unmethylated
DNA, MCA-Meth provides the possibility to detect an
intermediate status of methylation. We observed these
cases as peaks in an intermediate position, when com-
pared to the unmethylated and methylated control peaks
(Figure 3, U87MG cell line). Temperature transition rates
and concentration of salt and dye may have a significant
impact on the width and absolute position of a PCR prod-
uct's melting peak [22]. We observed a variation of 1°C
for the unmethylated blood DNA peak and 1.5°C for the
in vitro methylated DNA peak (negative and positive con-
trols, respectively) as a normal variation between different
experiments (data obtained from the comparison among
20–30 experiments for each gene, data not shown). To vis-
ualize and ensure the respective methylation status, both
controls were bisulfite-sequenced prior to further experi-
ments.
Both MCA-MSP and MCA-Meth have been proven here to
reliably detect promoter methylation. However, the
results obtained with these techniques versus standard
MSP were not the same in some cases. These aberrant
results may highlight advantages and shortcomings of
both standard MSP and MSP-derived assays and MCA-
Meth and may root in the different technical approaches
of these assays. As mentioned above in standard MSP only
the CpGs incorporated into the primer sequences decide
on the methylation status of the gene promoter as a
whole. Therefore MSP and MSP-derived methods depend
on homogeneous methylation patterns at their respective
priming sites. MCA-Meth, however, is independent of
homogeneous methylation patterns as the priming sites
are devoid of CpG-dinucleotide residues. Rather, melting
curve peak position in relation to unmethylated and
methylated DNA controls decides on the promoter meth-
ylation status. This independence of homogeneous prim-
ing site methylation patterns makes the analysis of
inhomogeneously methylated DNA samples possible. The
results may also better correlate with sequencing data, as
the melting curve peak position shifts to a higher temper-
ature the more CpGs are methylated within a given
sequence. In cases with inhomogeneously methylated
MSP priming sites MCA-Meth may be superior to standard
MSP. Also, there is the possibility that sequence methyla-
tion in between the MSP-primers significantly impacts the
extent of gene silencing and differs among samples with
homogeneously methylated priming sites. This would
lead to the overestimation of promoter hypermethylation
and to false positive results unwanted in a diagnostic set-
ting. Bisulfite sequencing easily closes that gap, as it
reflects the CpG dinucleotide methylation status of the
sequenced promoter region. Yet, it necessitates good qual-
ity DNA, as the sequenced fragment usually exceeds the
size of a MSP product. Also, it calls for cloning the frag-
ments into plasmids in order to secure clean sequencing
results. For semiquantification, multiple clones have to be
sequenced and all CpGs within the sequence have to be
analyzed after sequencing, making bisulfite-sequencing a
time- and labor-consuming technique, not suited for fast-
track diagnostic testing. In these situations MCA-Meth
may proof a useful alternative screening tool.
Standard MSP will, however, be superior to MCA-Meth in
cases in which priming site methylation is homogene-
ously found and reliably predicts gene silencing. Again
MSP priming site methylation may be homogeneous for
these promoters, but methylation frequency may differ in
the sequence between the primers. In those situations it is
conceivable that MCA-Meth yields results that are hard to
interpret as it does not detect the priming site methylation
status but rather relies on the methylation pattern of the
whole sequence analyzed.
Figure 3 shows the possible impact of inhomogeneous
priming site methylation on MSP results as well as the
influence of the extent of sequence methylation on MCA-
Meth. Bisulfite sequencing of sample 26 revealed an
almost completely unmethylated promoter except for par-
tial methylation of the first five to six CpGs of the CpG-
island (Figure 3). Even though these methylated CpG-res-
idues were part of the 5'-priming site selected for MSP
primers, MSP was significant for an unmethylated pro-
moter, as well. The explanation for the seemingly para-
doxical MSP result may lie in both the homogeneous 3'-
priming site methylation pattern and an inhomogeneous
5'-priming site methylation coupled with differences in
M- and U-primer design. As documented in bisulfite
sequencing all four clones harbor a completely unmethyl-
ated 3'-priming site. Primer sequences of both M- and U-
primers cover the same 4 CpG-dinucleotides of the CpG-
island. As these CpGs (CpG 24–27) are unmethylated inPage 11 of 14
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BMC Cancer 2008, 8:61 http://www.biomedcentral.com/1471-2407/8/61all clones, 3'-mispriming seems impossible. The 5'-prim-
ing site is inhomogeneously methylated with either the
first five or six CpGs methylated in bisulfite sequencing.
We sequenced four clones only, but it seems conceivable
that with an inhomogeneous methylation pattern on the
5'-priming site, there may be clones in which less than the
first five CpGs are methylated. As the 3'-priming site
already selects for the unmethylated allele, only a few cop-
ies of a less methylated 5'-priming site would suffice to
yield an unmethylated promoter, explaining the MSP
result. What is more as the 5'-priming site for the unmeth-
ylated variant of the MGMT-promoter exceeds the 5'-
priming site for the methylated variant by one CpG-dinu-
cleotide (Figure 3). The additional CpG dinucleotide lies
on the 3'-end of the U-primer. Primer annealing at the 3'-
end is of more importance for successful DNA amplifica-
tion. As methylation seems to be more inhomogeneous at
the 3'-end of the small promoter fragment it is even more
likely for the U-primer to find a suitable template. MCA-
Meth, in accordance with the sequencing data, also sug-
gested an unmethylated promoter. However, the melting
point peak position was slightly shifted towards a higher
temperature; the curve itself seemed broadened and
revealed a "shoulder". These changes in melting curve
position and form may mirror the methylated state of the
first 5–6 CpGs. While the position indicates a not com-
pletely unmethylated promoter, the width and shoulder
of the curve suggests heterogeneity of promoter methyla-
tion in the sample. Thus, in MCA-Meth the extent of
sequence methylation would determine the melting curve
peak position while the heterogeneity of that sequence
methylation would influence the melting curve appear-
ance. The MCA-Meth result of U87MG illustrates the fea-
sibility of the hypothesis that the extent of promoter
methylation alters the melting curve peak position (Figure
3). Bisulfite sequencing of the fragment covered in the
MCA-Meth analysis (CpGs -1 to 20 of the CpG island)
revealed an inhomogeneous methylation pattern of that
sequence. Accordingly the melting curve peak in MCA-
Meth shifted to a position in between the hypermethyl-
ated and completely unmethylated controls (Figure 3). As
both the 5'- and 3'-MSP-priming site were homogene-
ously methylated, MSP was significant for a methylated
promoter. Thus in MCA-Meth a single shifted melting
point position reflects the extent of sequence methylation
and the shape of the melting curve indicates the heteroge-
neity of promoter methylation. Thus, should it be neces-
sary to analyze the physiological relevance of the
percentage of methylated CpG-sites in a given promoter
or to define a threshold of methylated cytosines in a par-
ticular gene required for its silencing, MCA-Meth may pro-
vide a simple tool among the commonly used techniques
to detect inhomogeneous methylation, besides bisulfite
sequencing.
Our results encourage a back-to-back comparison of
MCA-Meth and bisulfite sequencing in a large series of
tumors harboring different numbers of methylated CpG
dinucleotide residues in their sequence. This analysis will
provide answers regarding the sensitivity and specificity of
MCA-Meth in the detection of promoter methylation
extent. It will also show the limits of this technique and
will decide on its priority future use.
Another scenario is the co-detection of methylated and
unmethylated alleles in the same sample represented by
two distinct melting points. A co-detection of methylated
and unmethylated alleles can be due to sample contami-
nation with normal tissue or reflect single allelic promoter
methylation. Here the respective peak heights if compared
to a dilution series of methylated and unmethylated DNA
may predict the prevailing methylation status. The data on
RASSF1A-promoter methylation of glioma sample 7 and
30 may illustrate the significance of this distinction.
Standard MSP co-detected methylated and unmethylated
alleles in both samples. MSP failed to identify the prevail-
ing methylation pattern. MCA-Meth, however, suggested
the presence of less than 5% of methylated DNA for sam-
ples 7 compared to 72% of methylated DNA for sample
30 (Table 4). The prevailing methylation status was thus
an unmethylated promoter for sample 7 and a methylated
promoter for sample 30. Bisulfite sequencing supported
these MCA-Meth data revealing an almost completely
unmethylated promoter in sample 7 and a heavily meth-
ylated promoter in sample 30.
Of note, besides MCA-Meth there are several alternative
techniques to reliably detect intermediate levels of pro-
moter methylation, i.e. rtMSP, pyrosequencing and
MALDI-TOF. However, in contrast to MCA-Meth these are
more cost intensive and are in need for expensive hard-
ware that is not easily accessible in some institutions. The
all-in-one tube reaction of MCA-Meth avoiding a gel stage
further adds to the advantages for MCA-Meth in screening
or diagnostic settings.
We have described two methods that use bisulfite modi-
fied DNA and Melting Curve Analysis (MCA) to assess
DNA methylation. Using the 5'-CpG island in the
RASSF1A, BLU and MGMT gene promoters as a model sys-
tem, we have demonstrated here that both MCA-MSP and
MCA-Meth can be used to determine the methylation sta-
tus in tumor samples and have discussed their advantages
and possible shortcomings as compared to commonly
used techniques for promoter methylation analyses.
Conclusion
In our view, MCA-Meth combines the advantages of both
MSP and bisulfite sequencing. Similar to MSP it is able to
answer the question, whether a sample is hypermethyl-Page 12 of 14
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BMC Cancer 2008, 8:61 http://www.biomedcentral.com/1471-2407/8/61ated or not. The advantage over the MSP is that it also
addresses the question of the extent of promoter methyla-
tion, without going into the trouble of cloning, sequenc-
ing and analyzing each and every CpG, a major advantage
over bisulfite sequencing. We do see however some
restrictions to MCA-Meth in those diagnostic applications
in which homogeneous priming-site-methylation reliably
predicts gene silencing. Here, an heterogeneous sequence
methylation status in between MSP primers may give
ambiguous results in MCA-Meth and may need a second
evaluation by standard MSP, MCA-MSP or bisulfite
sequencing. Also, even so MCA-Meth provides data on the
extent of promoter methylation it does not quantify the
methylation status of individual CpG dinucleotides
within the sequence. In these settings MCA-Meth may
serve as a technically easy and almost ubiquitously avail-
able initial screening tool, followed up by more sophisti-
cated quantitative techniques for selected candidates.
Those limitations apart, the advantages of MCA-MSP and
MCA-Meth as outlined above prevail. Both may be used as
feasible diagnostic tools for the majority of applications.
MCA-Meth may in addition proof an alternative tech-
nique to fast screen for different levels of promoter hyper-
methylation.
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